The Association Between TNF Inhibitor Therapy Availability and Hospital Admission Rates for Patients with Ankylosing Spondylitis. A Longitudinal Population-Based Study

[1]  N. Bragazzi,et al.  Mortality in Ankylosing Spondylitis According to Treatment: A Nationwide Retrospective Cohort Study of 5,900 Patients From Israel , 2021, Arthritis care & research.

[2]  Catherine M. Lockhart,et al.  Utilization patterns and characteristics of users of biologic anti‐inflammatory agents in a large, US commercially insured population , 2020, Pharmacology research & perspectives.

[3]  S. Ramiro,et al.  Work Disability in Axial Spondyloarthritis , 2020, Current Rheumatology Reports.

[4]  T. Tomita,et al.  Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis , 2020, Modern rheumatology.

[5]  V. Strand,et al.  Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study , 2020, BMC Rheumatology.

[6]  C. Inderjeeth,et al.  The Risk and Consequences of Vertebral Fracture in Patients with Ankylosing Spondylitis: A Population-based Data Linkage Study , 2020, The Journal of Rheumatology.

[7]  M. Nørgaard,et al.  Ankylosing spondylitis and mortality following hospitalised pneumonia: a population-based cohort study , 2020, RMD Open.

[8]  J. Branco,et al.  Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI , 2020, RMD Open.

[9]  Tae-Hwan Kim,et al.  Gastrointestinal risk factors and patient‐reported outcomes of ankylosing spondylitis in Korea , 2019, International journal of rheumatic diseases.

[10]  M. Nurmohamed,et al.  Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review , 2019, Expert opinion on biological therapy.

[11]  J. Vencovský,et al.  Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry , 2019, Expert opinion on biological therapy.

[12]  X. Baraliakos,et al.  Treat to Target in Axial Spondyloarthritis. , 2019, Rheumatic diseases clinics of North America.

[13]  Yu Jeong Park,et al.  The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis , 2019, Journal of Korean medical science.

[14]  J. Branco,et al.  Psoriatic arthritis and Ankylosing Spondylitis Impact on Health-related Quality of Life and Working Life: A Comparative Population-Based Study. , 2019, Acta reumatologica portuguesa.

[15]  F. Hoffmann,et al.  Krankheitskosten bei axialer Spondyloarthritis für Patienten mit und ohne Tumor-Nekrose-Faktor-Inhibitor-Behandlung: Ergebnisse einer Routinedatenanalyse , 2019, Zeitschrift für Rheumatologie.

[16]  Li-Yu Hu,et al.  Should clinicians pay more attention to the potential underdiagnosis of osteoporosis in patients with ankylosing spondylitis? A national population-based study in Taiwan , 2019, PloS one.

[17]  W. Katchamart,et al.  Relationship Between Health-Related Quality of Life and Patient Acceptable Symptom State With Disease Activity and Functional Status in Patients With Ankylosing Spondylitis in Thailand , 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[18]  S. Grazio,et al.  Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries , 2018, Drugs in context.

[19]  G. Macfarlane,et al.  Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis , 2018, Annals of the rheumatic diseases.

[20]  F. Ursini,et al.  Safety of treatment options for spondyloarthritis: a narrative review , 2018, Expert opinion on drug safety.

[21]  M. Ward,et al.  Epidemiology of axial spondyloarthritis: an update , 2017, Current opinion in rheumatology.

[22]  W. Fan,et al.  Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials , 2017, Experimental and therapeutic medicine.

[23]  A. Ido,et al.  Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. , 2017, Journal of autoimmunity.

[24]  J. Paterson,et al.  Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality , 2015, Annals of Internal Medicine.

[25]  P. Tugwell,et al.  TNF-alpha inhibitors for ankylosing spondylitis. , 2015, The Cochrane database of systematic reviews.

[26]  H. Nossent,et al.  Epidemiology of Spondyloarthritis: A Review , 2013, Current Rheumatology Reports.

[27]  R. Buchbinder,et al.  Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. , 2012, The Cochrane database of systematic reviews.

[28]  J. Gran,et al.  Increased mortality in ankylosing spondylitis is related to disease activity , 2011, Annals of the rheumatic diseases.

[29]  J. Gran,et al.  Work Disability in Patients with Ankylosing Spondylitis in Norway , 2011, The Journal of Rheumatology.

[30]  W. Maksymowych,et al.  A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis , 2010, The Journal of Rheumatology.

[31]  M. Dougados,et al.  An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis , 2006, Annals of the rheumatic diseases.

[32]  B. Aggarwal,et al.  Upside and Downside of Tumor Necrosis Factor Blockers for Treatment of Immune/Inflammatory Diseases. , 2019, Critical reviews in immunology.